Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + daunorubicin + gilteritinib
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cytarabine + daunorubicin (or idarubicin) + gilteritinib is a combination chemotherapy regimen used for the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia (AML). This regimen integrates the standard '7+3' induction chemotherapy backbone—consisting of the antimetabolite cytarabine and an anthracycline (either daunorubicin or idarubicin)—with gilteritinib (Xospata), a potent oral small-molecule tyrosine kinase inhibitor. Gilteritinib selectively targets both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations of the FMS-like tyrosine kinase 3 (FLT3) receptor, as well as the AXL kinase, which is associated with resistance to FLT3 inhibitors. The combination aims to provide synergistic antileukemic activity by combining broad cytotoxic effects with targeted inhibition of key survival pathways in FLT3-mutated blasts. It is currently being evaluated in Phase III clinical trials as a standard-of-care comparator against novel triplet regimens.
- Brand names
- Xospata
- Other names
- cytarabine + idarubicin + gilteritinib7+3 chemotherapy plus gilteritinib3+7 chemotherapy plus gilteritinibstandard chemotherapy plus gilteritinib
02
Targets
AXL (AXL receptor tyrosine kinase)DNATOP2A (DNA topoisomerase II)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on cytarabine + daunorubicin + gilteritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + daunorubicin + gilteritinib.